Fundamental Analysis of NURIX THERAPEUTICS INC(NASDAQ:NRIX) stock

Fundamental Rating

NRIX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 586 industry peers in the Biotechnology industry. The financial health of NRIX is average, but there are quite some concerns on its profitability. NRIX is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NRIX has reported negative net income.

In the past year NRIX has reported a negative cash flow from operations.

NRIX had negative earnings in each of the past 5 years.

NRIX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

NRIX has a Return On Assets (-46.29%) which is in line with its industry peers.

NRIX's Return On Equity of -85.77% is in line compared to the rest of the industry. NRIX outperforms 48.55% of its industry peers.

		Industry Rank	Sector Rank
ROA	-46.29%
ROE	-85.77%
ROIC	N/A

ROA(3y)-36.11%

ROA(5y)-33.71%

ROE(3y)-55.14%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NRIX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NRIX does not have a ROIC to compare to the WACC, probably because it is not profitable.

NRIX has more shares outstanding than it did 1 year ago.

NRIX has more shares outstanding than it did 5 years ago.

NRIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of 0.70, we must say that NRIX is in the distress zone and has some risk of bankruptcy.

NRIX has a better Altman-Z score (0.70) than 61.71% of its industry peers.

NRIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	0.7

ROIC/WACCN/A

WACC9.02%

2.3 Liquidity

A Current Ratio of 2.86 indicates that NRIX has no problem at all paying its short term obligations.

NRIX's Current ratio of 2.86 is on the low side compared to the rest of the industry. NRIX is outperformed by 68.21% of its industry peers.

NRIX has a Quick Ratio of 2.86. This indicates that NRIX is financially healthy and has no problem in meeting its short term obligations.

With a Quick ratio value of 2.86, NRIX is not doing good in the industry: 66.67% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	2.86
Quick Ratio	2.86

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NRIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.65%, which is quite impressive.

The Revenue has grown by 94.04% in the past year. This is a very strong growth!

The Revenue has been growing by 15.50% on average over the past years. This is quite good.

EPS 1Y (TTM)24.65%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-1.33%

Revenue 1Y (TTM)94.04%

Revenue growth 3Y62.87%

Revenue growth 5Y15.5%

Revenue growth Q2Q30.69%

3.2 Future

Based on estimates for the next years, NRIX will show a small growth in Earnings Per Share. The EPS will grow by 7.32% on average per year.

The Revenue is expected to grow by 28.65% on average over the next years. This is a very strong growth

EPS Next Y-20.63%

EPS Next 2Y-9.43%

EPS Next 3Y-7.29%

EPS Next 5Y7.32%

Revenue Next Year-16.84%

Revenue Next 2Y-5.1%

Revenue Next 3Y17.77%

Revenue Next 5Y28.65%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NRIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year NRIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

NRIX's earnings are expected to decrease with -7.29% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-9.43%

EPS Next 3Y-7.29%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NRIX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NURIX THERAPEUTICS INC

NASDAQ:NRIX (5/17/2024, 7:16:35 PM)

After market: 16.59 0 (0%)

16.59

+1.19 (+7.73%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap983.79M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-46.29%
ROE	-85.77%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.26

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.86
Quick Ratio	2.86
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)24.65%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-20.63%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)94.04%

Revenue growth 3Y62.87%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

NURIX THERAPEUTICS INC (NRIX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens